UPDATE: Barrington Research Initiates LeMaitre Vascular at Outperform on Valuation, Stable Outlook
Barrington Research initiated coverage on LeMaitre Vascular (NASDAQ: LMAT) with an Outperform rating and a $7.50 price target.
Barrington Research commented, "We are initiating coverage of LMAT with an OUTPERFORM investment rating and a $7.50 price target based on our belief that LMAT has built a strong and sustainable business in the vascular surgery market and its valuation is very attractive. … With a strong surgical product portfolio, a knowledgeable and focused sales force, good relationships with a large percentage of vascular surgeons, LMAT is looking to leverage these market leadership positions by offering complementary products in larger, more competitive markets. LMAT has been an astute acquirer the past 15 years and we expect this strategy to continue."
LeMaitre Vascular closed at $5.98 on Thursday.
Latest Ratings for LMAT
|May 2016||Canaccord Genuity||Maintains||Buy|
|May 2016||Roth Capital||Maintains||Buy|
|Apr 2016||Cowen & Co.||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.